Compare Moderna, Inc. (MRNA) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Toronto-Dominion Bank — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Toronto-Dominion Bank trades at $115.1 (market cap $185.79B). The key difference: Toronto-Dominion Bank is far larger — about 2.4× Moderna, Inc.'s market cap, and Toronto-Dominion Bank pays a 2.84% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Toronto-Dominion Bank for 84 Days on average.
| MRNA | TD | |
|---|---|---|
Market Cap | $78.65B | $185.79B |
Volume | 37,373,437 | 3,263,867 |
Sector | Health | Financials |
52-Week High | $225.00 | $124.80 |
52-Week Low | $22.36 | $78.32 |
Typical Hold Time | 59 Days | 84 Days |
Enterprise Value | $74.80B | $559.06B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
TD Bank trades at $114.04, up 0.15% with a P/E of 17.36 and strong profitability metrics including 24.88% net income margin. Recent earnings have consistently beaten expectations, with three consecutive quarterly beats. Technical indicators show bearish momentum despite oversold RSI readings. The company announced a $10 billion share buyback program and $108 billion Canadian infrastructure commitment, signaling confidence in future growth.
The outlook remains positive with analyst consensus favoring Buy ratings (52.94%) and strong fundamentals, though technical weakness and increasing debt-to-asset ratios present near-term challenges. Revenue growth trajectory from $61.3B to projected $65.1B supports long-term investment case, while volatile cash flows require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
